相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Hepatic Arterial Infusion of Oxaliplatin Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
Qi-Jiong Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)
Ning Lyu et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Sorafenib Plus Hepatic ArterialInfusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized TriaL
Kanglian Zheng et al.
RADIOLOGY (2022)
AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma
Grace L. Su et al.
GASTROENTEROLOGY (2022)
Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations
Anthony C. Bejjani et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2022)
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
Zhenwei Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
R. S. Finn et al.
ANNALS OF ONCOLOGY (2022)
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma
Jianfeng Guo et al.
MOLECULAR CANCER (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma
Jingjun Huang et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo et al.
LIVER CANCER (2021)
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Roman M. Chabanon et al.
NATURE REVIEWS CANCER (2021)
Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein
Yumi Kosaka et al.
LIVER CANCER (2021)
Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition)
Shuqun Cheng et al.
LIVER CANCER (2020)
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Jian Zhou et al.
LIVER CANCER (2020)
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial
MinKe He et al.
JAMA ONCOLOGY (2019)
Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study
Xubiao Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
Fernando G. Herrera et al.
LANCET ONCOLOGY (2019)
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
Jian Lu et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma
Ning Lyu et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Vogel et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
Junji Matsui et al.
CLINICAL CANCER RESEARCH (2008)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)